These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32885992)

  • 61. Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin.
    Warrell RP; Israel R; Frisone M; Snyder T; Gaynor JJ; Bockman RS
    Ann Intern Med; 1988 May; 108(5):669-74. PubMed ID: 3282463
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Hypercalcemia as an emergency].
    Rosenmund A
    Schweiz Med Wochenschr; 1993 Apr; 123(15):735-8. PubMed ID: 8488377
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bisphosphonate treatment of tumor-induced hypercalcemia in a toddler: case report and review of related literature.
    Mastrandrea LD; Albini CH
    Endocr Pract; 2006; 12(6):670-5. PubMed ID: 17229665
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of Hypercalcemia of Malignancy.
    Chakhtoura M; El-Hajj Fuleihan G
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Salmon calcitonin in the acute management of hypercalcemia.
    Wisneski LA
    Calcif Tissue Int; 1990; 46 Suppl():S26-30. PubMed ID: 2137363
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The management of malignant hypercalcaemia.
    Watters J; Gerrand G; Dodwell D
    Drugs; 1996 Dec; 52(6):837-48. PubMed ID: 8957154
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Current and future directions in medical therapy: hypercalcemia.
    Body JJ
    Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bisphosphonates for treatment of childhood hypercalcemia.
    Lteif AN; Zimmerman D
    Pediatrics; 1998 Oct; 102(4 Pt 1):990-3. PubMed ID: 9755274
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hypercalcemia of malignancy: diagnosis and therapy.
    Fetchick DA; Mundy GR
    Compr Ther; 1986 Aug; 12(8):27-32. PubMed ID: 2943551
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
    Bassatne A; Murad MH; Piggott T; Drake MT; Rahme M; El-Hajj Fuleihan G
    J Clin Endocrinol Metab; 2023 Feb; 108(3):563-584. PubMed ID: 36545699
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypercalcemia and childhood cancer: a 7-year experience.
    Kerdudo C; Aerts I; Fattet S; Chevret L; Pacquement H; Doz F; Michon J; Garabedian M; Orbach D
    J Pediatr Hematol Oncol; 2005 Jan; 27(1):23-7. PubMed ID: 15654274
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative effects of calcitonin and clodronate in hypercalcaemia.
    Ljunghall S; Rastad J; Akerström G
    Bone; 1987; 8 Suppl 1():S79-83. PubMed ID: 2961359
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Zoledronic acid.
    Cheer SM; Noble S
    Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Denosumab in hypercalcemia of malignancy: a case series.
    Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
    J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
    Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
    Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
    Davis JR; Heath DA
    Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
    Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
    Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.